Literature DB >> 26293206

Acute resolution of pulmonary alveolar infiltrates in 10 dogs with pulmonary hypertension treated with sildenafil citrate: 2005-2014.

Heidi B Kellihan1, Kenneth R Waller2, Alyssa Pinkos2, Howard Steinberg2, Melissa L Bates3.   

Abstract

OBJECTIVE: To describe clinical canine patients with naturally occurring pulmonary hypertension and radiographic pulmonary alveolar infiltrates before and after treatment with sildenafil. ANIMALS: Ten client-owned dogs.
METHODS: A retrospective analysis of dogs with echocardiographically-determined pulmonary hypertension and pulmonary alveolar infiltrates on thoracic radiographs was performed before (PRE) and after (POST) sildenafil therapy. Clinical scores, pulmonary alveolar infiltrate scores and tricuspid regurgitation gradients were analyzed PRE and POST sildenafil.
RESULTS: Pulmonary alveolar infiltrates associated with pulmonary hypertension developed in a diffusely patchy distribution (10/10). Sixty percent of dogs had a suspected diagnosis of interstitial pulmonary fibrosis as the etiology of pulmonary hypertension. Median PRE clinical score was 4 (range: 3-4) compared to POST score of 0 (0-2) (p = 0.005). Median alveolar infiltrate score PRE was 10 (5-12) compared to POST score of 4 (0-6) (p = 0.006). Median tricuspid regurgitation gradient PRE was 83 mmHg (57-196) compared to 55 mmHg POST (33-151) (p = 0.002).
CONCLUSIONS: A subset of dogs with moderate to severe pulmonary hypertension present with diffuse, patchy alveolar infiltrates consistent with non-cardiogenic pulmonary edema. The typical clinical presentation is acute dyspnea and syncope, often in conjunction with heart murmurs suggestive of valvular insufficiency. This constellation of signs may lead to an initial misdiagnosis of congestive heart failure or pneumonia; however, these dogs clinically and radiographically improve with the initiation of sildenafil.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Interstitial pulmonary fibrosis; Pulmonary edema; Pulmonary infiltrate score; Quality of life score; Tricuspid regurgitation

Mesh:

Substances:

Year:  2015        PMID: 26293206     DOI: 10.1016/j.jvc.2015.04.002

Source DB:  PubMed          Journal:  J Vet Cardiol        ISSN: 1760-2734            Impact factor:   1.701


  17 in total

1.  Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study.

Authors:  J A Jaffey; S B Leach; L R Kong; K E Wiggen; S B Bender; C R Reinero
Journal:  J Vet Cardiol       Date:  2019-05-11       Impact factor: 1.701

2.  Adjunct ambrisentan therapy had clinical benefits in 5 dogs with sildenafil-refractory pulmonary hypertension.

Authors:  Seijirow Goya; Tomohiko Yoshida; Shigeharu Sennba; Tsuyoshi Uchide; Ryou Tanaka
Journal:  Can Vet J       Date:  2022-05       Impact factor: 1.075

3.  Unmasking of left heart dilation following treatment for precapillary pulmonary hypertension.

Authors:  Sarah Rogg; Justin D Thomason; Nathan Boyd
Journal:  Can Vet J       Date:  2021-11       Impact factor: 1.008

4.  Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog.

Authors:  Marjolein Lisette den Toom; Tetyda Paulina Dobak; Els Marion Broens; Chiara Valtolina
Journal:  Acta Vet Scand       Date:  2016-07-07       Impact factor: 1.695

5.  Pulmonary hypertension due to unclassified interstitial lung disease in a Pembroke Welsh corgi.

Authors:  Tomoya Morita; Kensuke Nakamura; Tatsuyuki Osuga; Atsushi Kobayashi; Osamu Ichii; Akira Yabuki; Mitsuyoshi Takiguchi
Journal:  J Vet Med Sci       Date:  2018-04-23       Impact factor: 1.267

6.  A syndrome of severe idiopathic pulmonary parenchymal disease with pulmonary hypertension in Pekingese.

Authors:  Liza S Köster; Robert M Kirberger
Journal:  Vet Med (Auckl)       Date:  2016-02-23

7.  Pulmonary complications in dogs with acute presentation of pancreatitis.

Authors:  Eleonora Gori; Alessio Pierini; Gianila Ceccherini; Simonetta Citi; Tommaso Mannucci; Ilaria Lippi; Veronica Marchetti
Journal:  BMC Vet Res       Date:  2020-06-22       Impact factor: 2.741

8.  ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs.

Authors:  Bruce W Keene; Clarke E Atkins; John D Bonagura; Philip R Fox; Jens Häggström; Virginia Luis Fuentes; Mark A Oyama; John E Rush; Rebecca Stepien; Masami Uechi
Journal:  J Vet Intern Med       Date:  2019-04-11       Impact factor: 3.333

9.  Clinical features of canine pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.

Authors:  Carol R Reinero; L Ari Jutkowitz; Nathan Nelson; Isabelle Masseau; Samuel Jennings; Kurt Williams
Journal:  J Vet Intern Med       Date:  2018-11-29       Impact factor: 3.333

10.  Effect of Body Position, Exercise, and Sedation on Estimation of Pulmonary Artery Pressure in Dogs with Degenerative Atrioventricular Valve Disease.

Authors:  J D Rhinehart; K E Schober; B A Scansen; V Yildiz; J D Bonagura
Journal:  J Vet Intern Med       Date:  2017-09-02       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.